The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment for severe low blood sugar levels (hypoglycaemia) in diabetics ...

It delivers a single 3mg dose into the nose via a single-use ... The efficacy and safety of Baqsimi was tested in two studies involving 83 and 70 adults with diabetes, which compared a single ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in 2026.